Vaxil Bio Ltd.
VXL.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 130.08% | 194.98% | 57.45% | 7.75% | -74.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.52% | 76.82% | -1.29% | -31.69% | -75.46% |
| Operating Income | -49.52% | -76.82% | 1.29% | 31.69% | 75.46% |
| Income Before Tax | 34.57% | 14.04% | 12.71% | 38.63% | 75.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 34.57% | 14.04% | 12.71% | 38.63% | 75.84% |
| Earnings from Discontinued Operations | 129.45% | -1.96% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 49.16% | 13.15% | 2.23% | 30.90% | 71.49% |
| EBIT | -49.52% | -76.82% | 1.29% | 31.69% | 75.46% |
| EBITDA | -- | -- | -- | -- | 106.87% |
| EPS Basic | 49.28% | 13.27% | 2.17% | 30.81% | 71.46% |
| Normalized Basic EPS | 31.25% | 13.95% | 12.89% | 38.75% | 77.26% |
| EPS Diluted | 49.28% | 13.27% | 2.17% | 30.81% | 71.46% |
| Normalized Diluted EPS | 31.25% | 13.95% | 12.89% | 38.75% | 77.26% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |